Nanotechnology Now - Press Release: Correlogic Systems and JEOL Sign Research and Development Agreement

Home > Press > Correlogic Systems and JEOL Sign Research and Development Agreement

Abstract:
Joint Efforts to Advance Clinical Application of Mass Spectrometry

Correlogic Systems and JEOL Sign Research and Development Agreement

ROCKVILLE, MD | Posted on June 6th, 2007

Correlogic Systems, Inc. and JEOL, Ltd. today announced the signing of a research and development
agreement focused on further enhancing the performance of mass spectrometry
in a clinical setting. JEOL, headquartered in Tokyo, is a leading global
manufacturer of scientific instruments used for research and development in
the fields of nanotechnology, life sciences, optical communication,
forensics, and biotechnology. Correlogic, based in Rockville, Maryland has
pioneered the use of pattern recognition technologies for the development
of proteomic, metabolomic, and genomic based clinical prognostic and
clinical diagnostic tests. Correlogic and JEOL have collaborated for more
than a year under an informal agreement, and have made great strides in the
continuing validation of various mass spectrometer-based assays. Details of
the agreement were not released.

Over the past year, we have had a very close and productive research
collaboration with JEOL," said Peter J. Levine, President and CEO of
Correlogic Systems, Inc. "This agreement formalizes our link to one of the
world's leading mass spectrometer and NMR manufacturers."

####

About Correlogic Systems, Inc.
Correlogic Systems, Inc. has developed patented technology and processes with a wide variety of applications for biomarker discovery, disease detection, and new drug discovery. The technology's first application has been in the field of proteomics -- the study of human proteins. OvaCheck(R), a blood test for the early detection of ovarian cancer, is Correlogic's first diagnostic test using its patented "Hidden Patterns" approach. The test is undergoing the final stages of its extensive validation process. Correlogic has entered into marketing
agreements with Quest Diagnostics, Inc., and Laboratory Corporation of America for North America. Mitsui & Co., Ltd. and Quest Diagnostics are equity investors in Correlogic. Visit Correlogic at http://www.correlogic.com .

About JEOL, Ltd. JEOL is a world leader in electron optical equipment
and instrumentation for high-end scientific and industrial research and
development. Core product groups include electron microscopes (SEMs and
TEMs), instruments for the semiconductor industry (electron beam
lithography and a series of defect review and inspection tools), and
analytical instruments including mass spectrometers, NMRs and ESRs.
Headquartered in Tokyo, Japan, the company has offices throughout the
world.

Cautionary Statement: Certain statements contained in this release are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements are based on management's
current expectations and are subject to uncertainty and changes in
circumstances. Actual results could differ materially due to, among other
things, operational and other difficulties associated with integrating
acquired business, general business conditions, competition among managed
care companies, rising health costs, trends in medical loss ratios, health
care reform, delay in receipt of regulatory and other approvals for pending
transactions and other regulatory issues.